Compare Enveric Biosciences Inc (ENVB) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Stanley Black & Decker, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Stanley Black & Decker, Inc. trades at $87.86 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 1980.9× Enveric Biosciences Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| ENVB | SWK | |
|---|---|---|
Market Cap | $6.80M | $13.47B |
Volume | 64,867 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $10.80 | $104.00 |
52-Week Low | $1.27 | $62.12 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.49M | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Stanley Black & Decker (SWK) trades at $88.31, down 1.87% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected November 4, 2026. Fundamentals show modest revenue of $15.13B in 2025 and a net income margin of 4.07%, while valuation ratios like a P/E of 21.8 and P/S of 0.89 suggest reasonable pricing. Recent news highlights product launches like the dustbuster® mini™ and management's focus on margin gains.
The outlook is mixed: analyst consensus is a 'Hold' with a $93 price target, implying ~5% upside, but technical weakness and competitive pressures pose risks. Investment appeal lies in its dividend king status and cost-saving initiatives, though investors face headwinds from higher expenses and market volatility. Earnings growth remains the key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
